AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:52:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -182.02900M | -191.54600M | -150.07200M | -84.48600M | -139.68600M |
| Minority interest | - | - | - | - | - |
| Net income | 28.78M | 194.24M | -138.06100M | -106.90600M | -126.75700M |
| Selling general administrative | 50.67M | 54.84M | 72.69M | 64.63M | 51.72M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | 0.00000M | 72.91M | 110.94M | 29.36M |
| Reconciled depreciation | 0.95M | 1.39M | 1.62M | 1.79M | 0.96M |
| Ebit | -163.38900M | -173.61700M | -110.60100M | -63.38200M | -111.40300M |
| Ebitda | -159.32700M | -171.87700M | -109.94700M | -61.82900M | -110.44100M |
| Depreciation and amortization | 4.06M | 1.74M | 0.65M | 1.55M | 0.96M |
| Non operating income net other | 4.06M | 1.74M | -12.72000M | 1.55M | -11.21200M |
| Operating income | -163.38900M | -173.61700M | -110.60100M | -63.38200M | -112.22200M |
| Other operating expenses | 163.39M | 173.62M | 184.41M | 175.19M | 142.09M |
| Interest expense | 22.70M | 19.67M | 26.75M | 22.66M | 16.25M |
| Tax provision | 0.00000M | 0.00000M | -12.01100M | 0.00000M | -12.92900M |
| Interest income | 4.06M | - | - | 22.66M | 16.25M |
| Net interest income | -18.64000M | -19.66900M | -26.75100M | -22.65700M | -16.25200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -210.80600M | -365.75800M | -12.01100M | 22.42M | -12.92900M |
| Total revenue | 0.00000M | 0.00000M | 73.81M | 111.81M | 29.87M |
| Total operating expenses | 163.39M | 173.62M | 183.51M | 174.32M | 141.58M |
| Cost of revenue | - | 0.00000M | 0.90M | 0.86M | 0.51M |
| Total other income expense net | -18.64000M | -17.92900M | -39.47100M | -21.10400M | -11.21200M |
| Discontinued operations | 229.45M | 385.78M | 385.78M | 385.78M | 385.78M |
| Net income from continuing ops | -182.02900M | -191.54600M | -138.06100M | -84.48600M | -126.75700M |
| Net income applicable to common shares | 47.42M | 194.24M | -138.06100M | -84.48600M | -126.75700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 378.27M | 590.97M | 419.27M | 181.04M | 136.97M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 8.58M | 6.30M | 8.15M | 11.14M | 6.62M |
| Total liab | 403.25M | 505.29M | 395.49M | 301.79M | 245.99M |
| Total stockholder equity | -24.98300M | 85.68M | 23.78M | -872.67200M | -734.61100M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 31.87M | 32.00M | 33.13M | 28.75M | 46.63M |
| Common stock | 0.61M | 721.40M | 0.63M | 0.62M | 0.54M |
| Capital stock | - | 0.63M | 0.63M | 0.62M | 0.54M |
| Retained earnings | -753.53000M | -635.71700M | -683.13400M | -872.67200M | -734.61100M |
| Other liab | - | 0.44M | 1.11M | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | 124.48M | 141.37M | 27.21M | 2.31M |
| Cash | 7.11M | 11.01M | 100.81M | 10.50M | 3.08M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 53.32M | 136.68M | 51.79M | 36.74M | 55.46M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | 354.48M | 331.01M | 247.03M | 22.05M | 32.74M |
| Short term debt | 13.74M | 98.69M | 5.25M | 3.78M | 3.50M |
| Short long term debt | - | 94.38M | - | - | - |
| Short long term debt total | 361.58M | 342.02M | 347.84M | 32.55M | 35.82M |
| Other stockholder equity | 727.94M | 720.77M | 706.29M | -0.61600M | -0.54200M |
| Property plant equipment | - | 23.25M | 30.01M | 28.08M | 3.83M |
| Total current assets | 217.90M | 443.24M | 247.89M | 151.28M | 103.75M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 233.24M | 52.91M | -91.98200M | -76.70300M |
| Short term investments | 164.74M | 183.91M | 56.46M | 124.45M | 57.70M |
| Net receivables | 37.47M | 242.02M | 82.47M | 3.84M | 35.19M |
| Long term debt | - | 220.91M | 313.46M | 236.29M | 158.21M |
| Inventory | - | - | - | 114.55M | 48.29M |
| Accounts payable | 7.71M | 5.99M | 13.40M | 4.20M | 5.33M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.00000M | - | - | - | -6.03500M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.63M | 0.63M | 0.62M | 0.54M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -635.71700M | -683.13400M | -872.67200M | -734.61100M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 139.79M | 124.48M | 141.37M | 1.68M | 2.31M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 160.37M | 147.73M | 171.38M | 29.76M | 33.22M |
| Capital lease obligations | - | 26.74M | 34.38M | 32.55M | 35.82M |
| Long term debt total | - | 220.91M | 313.46M | 236.29M | 158.21M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -127.45100M | 67.99M | -66.74800M | -3.06700M | 25.72M |
| Change to liabilities | -10.66500M | 15.31M | -19.73600M | 13.28M | 10.54M |
| Total cashflows from investing activities | -127.56400M | 193.71M | -67.03100M | -3.40100M | 25.15M |
| Net borrowings | 0.04M | 0.29M | 92.61M | 1.44M | 107.50M |
| Total cash from financing activities | 124.25M | 6.32M | 174.53M | 60.70M | 81.05M |
| Change to operating activities | 66.76M | 5.57M | -3.81600M | -0.25100M | -0.49800M |
| Net income | 47.42M | 194.24M | -138.06100M | -84.48600M | -126.75700M |
| Change in cash | -89.79900M | 90.31M | 7.42M | -2.77700M | 2.47M |
| Begin period cash flow | 100.81M | 10.50M | 3.08M | 5.86M | 3.39M |
| End period cash flow | 11.01M | 100.81M | 10.50M | 3.08M | 5.86M |
| Total cash from operating activities | -86.48300M | -109.72200M | -100.08600M | -60.07300M | -103.73700M |
| Issuance of capital stock | 0.00000M | 0.00000M | 93.67M | 54.24M | 0.00000M |
| Depreciation | 0.95M | 1.39M | 1.62M | 1.79M | 0.96M |
| Other cashflows from investing activities | - | 125.99M | - | -3.06700M | 25.72M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 34.31M | -0.20800M | -1.05900M | 0.35M |
| Change to account receivables | -175.06600M | -34.31400M | 31.34M | -12.36700M | -6.17200M |
| Sale purchase of stock | 0.41M | 8.14M | 98.70M | 61.84M | 6.73M |
| Other cashflows from financing activities | 125.00M | 8.14M | 207.69M | 7.60M | 225.98M |
| Change to netincome | 14.07M | -292.93300M | 17.13M | 13.79M | 17.77M |
| Capital expenditures | 0.11M | 0.28M | 0.28M | 0.33M | 0.57M |
| Change receivables | -175.06600M | -34.31400M | 31.34M | -12.36700M | -5.67400M |
| Cash flows other operating | 34.98M | 4.90M | -3.81600M | -0.25100M | -0.93300M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -89.79900M | 90.31M | 7.42M | -2.77700M | 2.47M |
| Change in working capital | -118.96800M | -14.10600M | 7.58M | -0.39400M | 4.29M |
| Stock based compensation | 14.07M | 17.63M | 14.93M | 13.79M | 11.71M |
| Other non cash items | -29.95600M | 1.70M | 25.86M | 9.23M | 18.98M |
| Free cash flow | -86.59600M | -109.99900M | -100.36900M | -60.40700M | -104.30400M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| OMER Omeros Corporation |
3.27 43.83% | 10.73 | - | - | 4.93 | 8.44 | 8.26 | -1.9732 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
The Omeros Building, Seattle, WA, United States, 98119
| Name | Title | Year Born |
|---|---|---|
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & Pres | 1959 |
| Mr. Michael A. Jacobsen | Chief Accounting Officer, VP of Fin. & Treasurer | 1958 |
| Mr. Peter B. Cancelmo J.D. | VP, Gen. Counsel & Corp. Sec. | 1979 |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder | 1963 |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science | 1957 |
| Mr. Peter W. Williams | VP of HR | 1968 |
| Dr. J. Steven Whitaker J.D., M.D. | VP of Clinical Devel. & Chief Medical Officer | 1956 |
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems | 1959 |
| Ms. Nadia Dac | VP & Chief Commercial Officer | 1970 |
| Ms. Debra K. Bowes M.T | Chief Bus. Devel. Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...